Polaryx Therapeutics (PLYX) : 3-week performance

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 11
• Founded by Hahn-Jun Lee in 2014 
• HQ: Paramus, New Jersey
• https://polaryx.com

The company focuses on developing patient-friendly, orally available small molecule therapies (and some gene therapy candidates) for rare pediatric lysosomal storage disorders (LSDs), such as neuronal ceroid lipofuscinosis (e.g., CLN2, CLN3), Krabbe disease, Sandhoff disease, and others.

• Lead Candidate: PLX-200 (a repurposed oral small molecule, e.g., based on gemfibrozil) targets multiple LSDs by promoting lysosome biogenesis, reducing inflammation, and protecting neuronal function.
• Pipeline: Includes PLX-100, PLX-300 (preclinical combinations), and PLX-400 (preclinical gene therapy).